EasyDay Edibles partners with Paradigm Partners and Brands to launch a multi-patented, battery-free cannabis inhaler in Washington, D.C.

A December 18, 2025 executive order shifts cannabis from Schedule I to Schedule III. Here’s how that could reshape taxes, research, and patient access across the DMV.

Federal health officials and clinical experts met in Silver Spring to establish safety, credentialing, and access standards for psychedelic medicines.

Latest polling shows voters overwhelmingly opposing Question 8 as the election approaches, signaling strong support for adult-use markets.

Empire State regulators vow enforcement against illegal hemp THC beverage sales as grey-market retail operations surge outside licensed stores.

Explore how employer-sponsored medical cannabis benefits are cutting healthcare costs, backed by clinical research and DMV access updates.

HRSA logged 59 comments on training and outpatient delivery models for potential FDA‑approved psychedelic therapies. We unpack what’s being explored, plus why credentials, clinics, and costs matter.

Hawaii banned smokable hemp in 2020 but largely left it on shelves until a 2026 enforcement push. Retailers sued as the state cites prior law, a new registry, and federal THC rule changes.

Aurora told shareholders not to tender to Curaleaf’s hostile bid and signaled it’s weighing alternatives, sharpening focus on valuation, upside sharing, and voting control.